OSI Pharmaceuticals : Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma

Jul 15, 2008 - OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that it has initiated a Phase I clinical trial of OSI-027, an oral, potent and selective inhibitor of both the TORC1 and TORC2 complexes that inhibits the kinase activity associated with mTOR (mammalian target of rapamycin). The study is designed to determine the maximum tolerated dose (MTD) and to establish the recommended dose and dosing schedule for Phase II trials, and will evaluate the safety and pharmacokinetic profiles of OSI-027. Preclinical studies demonstrated that orally administered OSI-027 has the potential for anti-tumor efficacy in a broad range of human cancers that depend on the mTOR pathway for tumor growth and survival, such as ovarian, colorectal, breast, lung, prostate and brain cancers, in addition to lymphoma... OSI Pharmaceuticals' Press Release -

Abbott, Genentech, Roche and OSI, Collaboration on Molecular Test for Lung Cancer Therapy Response

March 7, 2008 -Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer - Abbott (NYSE: ABT) announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva® (erlotinib), an oral tablet indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Under the agreement, Abbott will develop a test to detect extra copies of the epidermal growth factor receptor (EGFR) gene using its proprietary fluorescence in situ hybridization (FISH) technology in NSCLC... Abbott's Press Release -

OSI Pharmaceuticals, Patent Term Extension for Tarceva(R) (erlotinib)

Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that the Company has received Notice of Final Determination from the US Patent and Trademark Office that the patent for Tarceva(R) (erlotinib), US Patent No. 5,747,498, covering composition of matter, processes for its preparation, methods of treating cancer, and pharmaceutical compositions containing Tarceva has been extended through November 8, 2018. In addition to the composition of matter patent, OSI also has a crystalline polymorph patent (US Patent No. 6,900,221) for Tarceva which expires in 2020... OSI Pharmaceuticals' Press Release -

OSI Pharmaceuticals, Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting

Sep 07, 2007 - OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) provided a summary of selected data from over 58 studies involving the Company's lead product, Tarceva(R), presented during the 12th World Congress on Lung Cancer (WCLC) held September 2-6 in Seoul, Korea. Tarceva is currently approved in the United States as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, and in combination with gemcitabine chemotherapy for the first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer... OSI Pharmaceuticals' Press Releases -